Form 6-K — CureVac N.V.: publication in Nature of preclinical data from CV2CoV (November 18, 2021)

Summary

A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of November, 2021, Commission File Number 001-39446. It states that on November 18, 2021 the company issued a press release announcing the publication in Nature of preclinical data from its second-generation COVID-19 vaccine candidate, CV2CoV. The information is incorporated by reference into a Form F-3 registration statement, File No. 333-259613, and the press release is listed as Exhibit 99.1.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

FORM 6-K

REPORT
OF FOREIGN PRIVATE ISSUER

PURSUANT
TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES
EXCHANGE ACT OF 1934

For
the month of November, 2021

Commission
File Number: 001-39446

CureVac
N.V.

( Exact
Name of Registrant as Specified in Its Charter )

Friedrich-Miescher-Strasse
15, 72076

Tübingen,
Germany

+49
7071 9883 0

(Address
of principal executive office)

Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F | x | Form 40-F | ¨

Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes | ¨ | No | x

Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes | ¨ | No | x

On November 18,
2021, CureVac N.V. (the “Company”) issued a press release announcing the publication in Nature of preclinical data from their
second-generation COVID-19 vaccine candidate, CV2CoV.

The information
included in this Form 6-K (including Exhibit 99.1) is hereby incorporated by reference into the Company’s Registration
Statement on Form F-3 (File No. 333-259613).

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.

CUREVAC
 N.V.
By: | /s/
 Franz-Werner Haas, LLD, LLM
Chief
 Executive Officer

Date: November 18,
2021

EXHIBIT
INDEX

EXHIBIT
 NO. | DESCRIPTION
99.1 | CureVac
 N.V. Press Release dated November 18, 2021.

File and source

File

SEC_CVAC_6-K_filed2021-11-18_0001104659-21-140884.htm

Size

20,088 bytes

SHA-256

f5075b041673837b796b193c16b60b7f482cd20ff117fb77194431a92c36486f

Our copy

SEC_CVAC_6-K_filed2021-11-18_0001104659-21-140884.htm

Original

www.sec.gov